» Authors » Afroz S Mohammad

Afroz S Mohammad

Explore the profile of Afroz S Mohammad including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 21
Citations 450
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Kim M, Gupta S, Zhang W, Talele S, Mohammad A, Laramy J, et al.
Drug Metab Dispos . 2021 Dec; 50(3):277-286. PMID: 34887255
Bioluminescent imaging (BLI) is a powerful tool in biomedical research to measure gene expression and tumor growth. The current study examined factors that influence the BLI signal, specifically focusing on...
2.
Griffith J, Kim M, Bruce D, Peterson C, Kitto K, Mohammad A, et al.
J Pharmacol Exp Ther . 2021 Oct; 380(1):34-46. PMID: 34663676
Novel combinations of specific opioid agonists like loperamide and oxymorphindole targeting the - and -opioid receptors, respectively, have shown increased potency with minimized opioid-associated risks. However, whether their interaction is...
3.
Talele S, Zhang W, Burgenske D, Kim M, Mohammad A, Dragojevic S, et al.
J Pharmacol Exp Ther . 2021 Sep; 379(3):343-357. PMID: 34556535
The effective treatment of brain tumors is a considerable challenge in part because of the presence of the blood-brain barrier (BBB) that limits drug delivery. Glioblastoma multiforme (GBM) is an...
4.
Steffen K, Mohammad A, Roerig J, Mitchell J, Nelson C, Orcutt M, et al.
Obes Surg . 2021 Jul; 31(10):4289-4294. PMID: 34291361
Introduction/purpose: The objective of this research was to characterize the impact of Roux-en-Y gastric bypass (RYGB) on the pharmacokinetic properties of the pro-drug lisdexamfetamine and its active metabolite, d-amphetamine. Materials...
5.
Sandberg D, Kharas N, Yu B, Janssen C, Trimble A, Ballester L, et al.
J Neurosurg Pediatr . 2020 May; 26(2):127-135. PMID: 32357333
Objective: Chemotherapy infusions directly into the fourth ventricle may play a role in treating malignant fourth-ventricular tumors. This study tested the safety and pharmacokinetics of short-term and long-term administration of...
6.
Gampa G, Kenchappa R, Mohammad A, Parrish K, Kim M, Crish J, et al.
Sci Rep . 2020 Apr; 10(1):6524. PMID: 32300151
Glioblastoma, the most lethal primary brain cancer, is extremely proliferative and invasive. Tumor cells at tumor/brain-interface often exist behind a functionally intact blood-brain barrier (BBB), and so are shielded from...
7.
Nwafor D, Brichacek A, Mohammad A, Griffith J, Lucke-Wold B, Benkovic S, et al.
J Cent Nerv Syst Dis . 2019 Apr; 11:1179573519840652. PMID: 31007531
Sepsis is a systemic inflammatory disease resulting from an infection. This disorder affects 750 000 people annually in the United States and has a 62% rehospitalization rate. Septic symptoms range...
8.
Kim M, Laramy J, Mohammad A, Talele S, Fisher J, Sarkaria J, et al.
Drug Metab Dispos . 2019 Feb; 47(4):393-404. PMID: 30705084
Tyrosine kinase inhibitors that target the epidermal growth factor receptor (EGFR) have had success in treating EGFR-positive tumors, including non-small-cell lung cancer (NSCLC). However, developing EGFR inhibitors that can be...
9.
Gampa G, Kim M, Mohammad A, Parrish K, Mladek A, Sarkaria J, et al.
J Pharmacol Exp Ther . 2019 Jan; 368(3):446-461. PMID: 30622172
Targeted inhibition of RAF and MEK by molecularly targeted agents has been employed as a strategy to block aberrant mitogen-activated protein kinase (MAPK) signaling in melanoma. While the use of...
10.
Mohammad A, Adkins C, Shah N, Aljammal R, Griffith J, Tallman R, et al.
BMC Cancer . 2018 Dec; 18(1):1225. PMID: 30526520
Background: Brain tumor vasculature can be significantly compromised and leakier than that of normal brain blood vessels. Little is known if there are vascular permeability alterations in the brain adjacent...